|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400089325 |
|
最近更新日期: Date of Last Refreshed on: |
2024-09-05 17:11:45 |
|
注册时间: Date of Registration: |
2024-09-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
不同模式小脑θ爆发刺激联合皮层磁刺激治疗脑卒中后上肢痉挛的临床研究 |
|
Public title: |
Clinical Study on the Treatment of Upper Limb Spasticity after Stroke with Different Modes of Cerebellar Theta-burst Stimulation Combined with Cortical Magnetic Stimulation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
不同模式小脑θ爆发刺激联合皮层磁刺激治疗脑卒中后上肢痉挛的临床研究 |
|
Scientific title: |
Clinical Study on the Treatment of Upper Limb Spasticity after Stroke with Different Modes of Cerebellar Theta-burst Stimulation Combined with Cortical Magnetic Stimulation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陶峰 |
研究负责人: |
陶峰 |
|
Applicant: |
Tao Feng |
Study leader: |
Tao Feng |
|
申请注册联系人电话: Applicant telephone: |
+86 18930810280 |
研究负责人电话:
Study leader's |
+86 21 34189990 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dr.feng.tao@outlook.com |
研究负责人电子邮件: Study leader's E-mail: |
181897866@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市金山区龙航路1508号 |
研究负责人通讯地址: |
上海市金山区龙航路1508号 |
|
Applicant address: |
No. 1508 Longhang Road, Jinshan District, Shanghai |
Study leader's address: |
1508, Longhang Road, Jinshan District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属金山医院 |
||
|
Applicant's institution: |
Fudan University Affiliated Jinshan Hospital |
||
|
研究负责人所在单位: |
复旦大学附属金山医院 |
||
|
Affiliation of the Leader: |
Jinshan Hosptial of Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
JIEC 2023-S87 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属金山医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Approval letter of Jinshan Hospital, Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-11-30 00:00:00 | ||
|
伦理委员会联系人: |
安妮 |
||
|
Contact Name of the ethic committee: |
An Ni |
||
|
伦理委员会联系地址: |
上海市金山区龙航路1508号 |
||
|
Contact Address of the ethic committee: |
1508, Longhang Road, Jinshan District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 57039818 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
jsyyllwyh2018@163.com |
|
研究实施负责(组长)单位: |
复旦大学附属金山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jinshan Hosptial of Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市金山区龙航路1508号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1508, Longhang Road, Jinshan District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financing |
||||||||||||||||||||||
|
研究疾病: |
脑梗死;脑出血;偏瘫; |
||||||||||||||||||||||
|
Target disease: |
Cerebral infarction; Cerebral hemorrhage; Hemiplegia; |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究将通过观察不同模式的小脑θ爆发刺激联合皮层低频重复经颅磁刺激对脑卒中患者上肢痉挛的疗效,并进一步检测其神经电生理指标,探讨其可能的治疗机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to observe the efficacy of different modes of cerebellar theta-burst stimulation (TBS) combined with low-frequency repetitive transcranial magnetic stimulation (rTMS) of the cortex in treating upper limb spasticity in stroke patients. Furthermore, we will examine the neurophysiological indicators to explore the potential therapeutic mechanisms of this combined stimulation approach. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.①符合第四届全国脑血管疾病会议制定的“脑卒中”诊断标准,经影像学检查明确诊断;②20岁≤年龄≤75岁;③首发脑卒中,或既往有腔隙性脑梗但无后遗症;④病程3-12个月,近1周病情稳定;⑤神志清、无认知障碍、简易认知状态检查表(MMSE)≥24分,能配合评估及治疗;⑥存在偏瘫,患侧上肢改良Asworth分级 ≥2 级。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meet the diagnostic criteria for "stroke" established by the 4th National Cerebrovascular Disease Conference, with a definitive diagnosis confirmed by imaging examination; 2. Age ranging from 20 to 75 years old; 3. First-onset stroke, or a history of lacunar infarction without sequelae; 4. Disease duration of 3-12 months, with a stable condition in the past week; 5. Conscious and free from cognitive impairment, with a Mini-Mental State Examination (MMSE) score of ≥24, able to cooperate with assessment and treatment; 6. Presence of hemiplegia, with a Modified Ashworth Scale (MAS) grade of ≥2 for the affected upper limb. |
||||||||||||||||||||||
|
排除标准: |
1.①戴有起搏器、颅内或体内金属植入物或存在颅骨缺失;②有癫痫病史者,女性处于哺乳期或妊娠可能等;③伴有严重全身性疾病,如充血性心力衰竭者,高血压、糖尿病未能控制者;④上肢原有疾病影响治疗者,如上肢感染、关节手术、骨折、挛缩、截肢等;⑤存在严重视力、听力、言语障碍(如聋哑人)或精神障碍等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with pacemakers, intracranial or internal metal implants, or skull defects; 2. Patients with a history of epilepsy, women who are lactating or have a possibility of pregnancy; 3. Patients with severe systemic diseases, such as uncontrolled congestive heart failure, hypertension, or diabetes; 4. Patients with pre-existing upper limb conditions that may affect treatment, including upper limb infections, joint surgery, fractures, contractures, amputations, etc. 5. Patients with severe visual, auditory, or speech impairments (e.g., deaf-mute individuals) or psychiatric disorders. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-01 00:00:00至 To 2026-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-09-10 00:00:00 至 To 2025-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究负责人将受试者根据入院顺序编号,采用Excel软件生成60个随机数,并与患者编号一一对应,并按照生成的随机数的大小将患者排序,序号1~30为对照组,31~60为iTBS组,61~90为cTBS组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The study principal will assign unique identification numbers to the subjects based on their admission order. Excel software will then be used to generate 60 random numbers, which will be matched one-to-one with the patient identification numbers. The patients will be sorted according to the magnitude of the generated random numbers, with serial numbers 1-30 assigned to the control group, 31-60 to the iTBS group, and 61-90 to the cTBS group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲 |
|
Blinding: |
Double blind |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
采用中国临床试验注册中心的基于互联网的临床研究公共管理平台 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Internet based clinical research public management platform of China Clinical Trial Registration Center |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用中国临床试验注册中心的基于互联网的临床研究公共管理平台中自带的电子采集和数据管理系统,由研究者进行数据采集归类后上传至该系统。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The electronic collection and data management system built in the Internet based clinical research public management platform of the China Clinical Trial Registration Center is adopted, and the researchers collect and classify the data and upload them to the system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |